CLASSIC
Regimen
- Experimental
- adjuvant CapOx (capecitabine + oxaliplatin) x8 cycles over 6 months
- Control
- surgery (D2) only
Population
Stage II-IIIB gastric cancer after D2 gastrectomy (Korea/China/Taiwan)
Key finding
3y DFS 74% vs 59% (HR 0.56, 95% CI 0.44-0.72, p<0.0001); 5y OS 78% vs 69% (HR 0.66) per long-term follow-up
Source: PMID 22226517
Timeline
Guideline citations
- NCCN GASTRIC (p.38)
- CSCO GASTRIC 2025 (p.63)⚠️ OCR source